Regeneron Pharmaceuticals Stock Surged 60%, Here’s Why
Regeneron Pharmaceuticals (REGN)’s stock soared 60%, fueled less by modest revenue growth and more by a leap in investor optimism reflected in a 53% P/E jump. Behind the surge: a strong earnings beat, key FDA nods, and pipeline wins—though not without some production bumps. Let’s unpack what really moved the needle.
Below is an analytical breakdown of stock movement into key contributing metrics.
| 5302025 | 11262025 | Change | |
|---|---|---|---|
| Stock Price ($) | 488.9 | 784.6 | 60.5% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 14,085.7 | 14,247.8 | 1.2% |
| Net Income Margin (%) | 31.9% | 32.1% | 0.6% |
| P/E Multiple | 11.6 | 17.8 | 53.1% |
| Shares Outstanding (Mil) | 106.7 | 103.6 | 2.9% |
| Cumulative Contribution | 60.3% |
So what is happening here? The stock price surged 60%, driven mainly by a massive 53% rise in the P/E multiple, while revenue edged up 1.2% and net margin improved 0.6%. Let’s explore what fueled this shift.
Here Is Why Regeneron Pharmaceuticals Stock Moved
- This Strategy Pays You 8.7% While Lining Up MPWR at Bargain Prices
- What Could Light a Fire Under Microsoft Stock
- 3 Key Risks That Could Drag Down Meta Platforms Stock
- Cash Machine Trading Cheap – Fiserv Stock Set to Run?
- Is Recursion Pharmaceuticals Stock Attractive?
- Comfort Systems USA Stock’s Winning Streak May Not Be Over Yet
- Q3 2025 Earnings Beat: EPS $11.83 beat $9.73 estimates, revenue $3.75B also exceeded forecasts.
- Eylea HD FDA Approval: FDA approved Eylea HD for RVO and monthly dosing, boosting competitiveness.
- Dupixent sBLA Accepted: FDA granted priority review for Dupixent sBLA in allergic fungal rhinosinusitis.
- Cemdisiran P3 Success: Positive P3 NIMBLE trial for cemdisiran in gMG met primary and key secondary endpoints.
- Eylea HD Manuf. Issues: Delays in Eylea HD pre-filled syringe approval due to manufacturing concerns.
Our Current Assesment Of REGN Stock
Opinion: We currently find REGN stock attractive. Why so? Have a look at the full story. Read Buy or Sell REGN Stock to see what drives our current opinion.
Risk: A good way to gauge risk for Regeneron (REGN) is to see how much it fell during past market sell-offs. It plunged nearly 69% in the Dot-Com crash and about 58% in the Global Financial Crisis. Even smaller shocks hit hard—a 48% drop in 2018 and around 27% in both the Covid sell-off and recent inflation shock. This shows that despite Regeneron’s strong fundamentals, big market turmoil can still trigger significant declines.
REGN stock may have seen strong gains recently, but investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.